Готові списки джерел за темами / CAR-T therapy

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій
  6. Звіти організацій

Добірка наукової літератури з теми "CAR-T therapy"

Автор: Grafiati
Опубліковано: 12 квітня 2025
Оновлено: 26 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "CAR-T therapy".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "CAR-T therapy"

1

Singh, Yuvraj. "Chimeric Antigen Receptors T Cells (CAR T) Therapy." International Journal of Science and Research (IJSR) 13, no. 5 (2024): 1563–66. http://dx.doi.org/10.21275/sr24523173932.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

San Segundo, Lucrecia Yáñez. "CAR-T cell therapy." Medicina Clínica (English Edition) 156, no. 3 (2021): 123–25. http://dx.doi.org/10.1016/j.medcle.2020.05.030.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Neff Newitt, Valerie. "CAR T-Cell Therapy." Oncology Times 39, no. 20 (2017): 1. http://dx.doi.org/10.1097/01.cot.0000526653.15787.41.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Ahmad, Aamir. "CAR-T Cell Therapy." International Journal of Molecular Sciences 21, no. 12 (2020): 4303. http://dx.doi.org/10.3390/ijms21124303.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Jacobson, Caron, Amy Emmert, and Meredith B. Rosenthal. "CAR T-Cell Therapy." JAMA 322, no. 10 (2019): 923. http://dx.doi.org/10.1001/jama.2019.10194.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Kwon, Miji, and Hee Ho Park. "CAR-T Therapy Targeting Solid Tumor." KSBB Journal 35, no. 2 (2020): 95–104. http://dx.doi.org/10.7841/ksbbj.2020.35.2.95.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

L. Penney, Christopher, Boulos Zacharie, and Jean-Simon Duceppe. "Tucaresol-Cyclophosphamide Combination Therapy: Proposal for a Safe, Affordable Alternative to CAR T-Cell Therapy." Journal of Clinical Review & Case Reports 9, no. 12 (2024): 01–04. https://doi.org/10.33140/jcrc.09.12.02.

Повний текст джерела
Анотація:
Chimeric Antigen Receptor (CAR) T-cell therapy is a newer immunotherapeutic process in which genetic engineering is used to incorporate a receptor protein into a patient’s T-cells thereby permitting the modified T-cells to recognize and eradicate tumors. Initially, CAR T-cell therapy was reserved as a last resort when standard cancer treatments failed to provide significant efficacy but subsequently, CAR T-cell therapy is finding use against earlier stage cancers. Since 2017, seven CAR T-cell therapies have attained FDA approval for treatment of hematological cancers. The latest approval, Nove
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Testa, Ugo, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, and Giuseppe Leone. "CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES." Mediterranean Journal of Hematology and Infectious Diseases 16, no. 1 (2024): e2024031. http://dx.doi.org/10.4084/mjhid.2024.031.

Повний текст джерела
Анотація:
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells have been introduced in the therapy of B-cell lymphomas, B-ALLs and multiple myeloma.
 These therapeutic successes have triggered the application of CAR-T cell therapy to other hematologic tumors, including T-cell malignancies. However, the success of CAR-T cell therapies in T-cell neoplasms was
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Hosen, Naoki. "2) CAR T Cell Therapy." Nihon Naika Gakkai Zasshi 108, no. 3 (2019): 438–42. http://dx.doi.org/10.2169/naika.108.438.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Thoma, Clemens. "Developing CAR T cell therapy." Nature Reviews Urology 15, no. 3 (2018): 138. http://dx.doi.org/10.1038/nrurol.2018.4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "CAR-T therapy"

1

Bourbon, Estelle. "Developing logic-gated CAR T cells for saferT-cell lymphoma therapy." Electronic Thesis or Diss., université Paris-Saclay, 2025. http://www.theses.fr/2025UPASL006.

Повний текст джерела
Анотація:
La thérapie par cellules T à récepteur antigénique chimérique (CAR) est apparue comme l'une des percées les plus convaincantes dans le traitement du cancer au cours de la dernière décennie. Cependant, les résultats remarquables obtenus dans les hémopathies B ne se sont pas encore étendus aux lymphomes T (LT) où l'éventuelle toxicité « on-target off-tumor » a limité le développement d'approches similaires.Dans ce travail, nous avons développé une plateforme NOT-gate, tirant parti de la perte d'expression du CD7 dans les LT pour distinguer les cellules T tumorales des cellules T normales. Cette
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Ringwelski, Beth Anne. "Label-Free CD8+ T-cell Purification and Electroporation in Relation to CAR T-cell Therapy." Thesis, North Dakota State University, 2020. https://hdl.handle.net/10365/31881.

Повний текст джерела
Анотація:
Immunotherapy is becoming recognized as a superior treatment for cancer. In recent years, chimeric antigen receptor (CAR) therapy is among the immunotherapies that has had growing success rates. CAR T-cell therapy takes patient’s T-cells and encodes them with a CAR expressing gene, which can then target their cancer cells. However, there are some dangers associated with this therapy. If a cancer cell is mistakenly transfected with the CAR molecule, it can become resistant to the therapy. Using the electric properties of the cells, we have created a technique that can purify the T-cells from th
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Agliardi, Giulia. "Development of a Chimeric Antigen Receptor (CAR)-based T cell therapy for glioblastoma." Thesis, University College London (University of London), 2017. http://discovery.ucl.ac.uk/10025011/.

Повний текст джерела
Анотація:
High grade gliomas are aggressive brain tumours for which treatment is highly challenging due to the location within the central nervous system (CNS), which may reduce access of cytotoxic chemotherapy, and their infiltrative growth, which precludes complete surgical resection. Current treatment includes surgical removal – wherever possible - followed by radiotherapy and chemotherapy. However, recurrence is common, resulting in a survival of only 12 to 15 months after diagnosis. This highlights the need for new therapies. Chimeric antigen receptors (CARs) are synthetic molecules which combine t
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Xie, Yushu Joy. "Engineering VHH-based chimeric antigen receptor (CAR) T cell therapy for solid tumor treatment." Thesis, Massachusetts Institute of Technology, 2019. https://hdl.handle.net/1721.1/123070.

Повний текст джерела
Анотація:
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2019<br>Cataloged from PDF version of thesis.<br>Includes bibliographical references.<br>Chimeric antigen receptor (CAR) T cells are a promising cancer therapeutic, as they can specifically redirect the cytotoxic function of a T cell to a chosen target of interest. CAR T cells have been successful in clinical trials against hematological cancers, but have experienced low efficacy against solid tumors for a number of reasons, including a paucity of tumor-specific antigens to target and a highly immunosu
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Bento, Rui Pedro Garcia de Oliveira. "CAR-modified T cells targeted to CD19 antigen for lymphocytic leukemia." Master's thesis, Universidade de Aveiro, 2014. http://hdl.handle.net/10773/13445.

Повний текст джерела
Анотація:
Mestrado em Biomedicina Farmacêutica<br>Cellular immunotherapies, or Advanced Therapy Medicinal Products (ATMPs), are emerging as novel and specific therapeutic approaches to treat diseases, such as certain types of leukemias, which are difficult or impossible to treat with today’s biopharmaceutical products. Breakthroughs in basic, preclinical, and clinical science spanning cellular immunology, and cellprocessing technologies has allowed clinical applications of chimeric antigen receptor–based therapies. A recent example is CTL019, a lentivirus-based gene therapy for autologous T cells, acqui
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Pfeilschifter, Janina Marie. "Targeting B non-Hodgkin lymphoma and tumor-supportive follicular helper T cells with anti-CXCR5 CAR T cells." Doctoral thesis, Humboldt-Universität zu Berlin, 2021. http://dx.doi.org/10.18452/23169.

Повний текст джерела
Анотація:
CAR-T-Zell-Therapie ist eine vielversprechende neuartige Behandlungsform für Patienten mit aggressiven B-Zell Non-Hodgkin-Lymphomen (B-NHL). In dieser Arbeit wurde die anti-CXCR5 CAR-T-Zell-Therapie als Alternative zur anti-CD19 CAR-T-Zell-Therapie für die Behandlung von reifen B-NHLs untersucht. CXCR5 ist ein B-Zell-homing Rezeptor, der von reifen B Zellen und follikulären T-Helferzellen (TFH Zellen) exprimiert wird. TFH Zellen wurden als tumor-unterstützend in chronisch lymphatischer Leukämie (CLL) und im follikulären Lymphom (FL) beschrieben. Dieses Expressionsmuster erlaubt es, auf einziga
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Karlsson, Hannah. "CD19-targeting CAR T Cells for Treatment of B Cell Malignancies : From Bench to Bedside." Doctoral thesis, Uppsala universitet, Klinisk immunologi, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-232638.

Повний текст джерела
Анотація:
Immunotherapy for cancer is a young research field progressing at high speed. The first chimera of an antibody and a signaling chain was designed by Zelig Eshhar and was later further developed to enhance existing T cell therapy by combining a single-chain fragment of an antibody with the CD3 zeta chain of the TCR complex. T cells expressing these chimeric antigen receptors (CARs) could recognize and specifically kill tumor cells. However the T cells, lacked in persistence and tumor rejection did not occur. Thus, the CAR constructs have been improved by providing the T cell with costimulatory
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Wang, Valentine. "Improving Allogeneic CAR-T cells : HLA class I KO Virus Specific T cells to limit GvHD and graft rejection." Electronic Thesis or Diss., Université de Lorraine, 2024. https://docnum.univ-lorraine.fr/ulprive/DDOC_T_2024_0235_WANG.pdf.

Повний текст джерела
Анотація:
La thérapie CAR-T a transformé le traitement du cancer en modifiant les lymphocytes T pour cibler spécifiquement les antigènes tumoraux. Bien que cette approche ait montré un succès remarquable dans les hémopathies malignes à cellules B, le processus reste coûteux et long, car il nécessite la collecte et la modification des cellules du patient, ce qui peut retarder le traitement. De plus, certains patients, en raison de traitements antérieurs ou de maladies avancées, ne disposent pas de cellules viables, limitant l'accès à cette thérapie.Les cellules CAR-T allogéniques provenant de donneurs of
Стилі APA, Harvard, Vancouver, ISO та ін.
9

ALBERTI, GAIA. "Evaluation of a Tandem CD33-CD146 Chimeric Antigen Receptor (CAR) for the simultaneous targeting of Acute Myeloid Leukemia (AML) blasts and stromal cells in the niche." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2022. http://hdl.handle.net/10281/382304.

Повний текст джерела
Анотація:
La leucemia mieloide acuta (LMA) è la neoplasia ematologica maggiormente diagnosticata nei pazienti adulti (25%) e mentre rappresenta il 15-20% dei casi nei pazienti pediatrici. La chemioterapia convenzionale, che impiega antraciclina e citarabina, rappresenta il trattamento standard per l’LMA, con tassi di remissione completa dal 60% all'80% nei bambini e dal 40% al 60% negli adulti (>60 anni). Sfortunatamente, la ricaduta dopo tale terapia è comune e la sopravvivenza dei pazienti stimata a 5 anni è ancora inferiore al 30%. Risulta quindi di primaria importanza trovare alternative terapeutich
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Aichelin, Katharina [Verfasser], and Peter [Akademischer Betreuer] Angel. "Development of a CD22-specific chimeric antigen receptor (CAR) for the adoptive T cell therapy of leukemia and lymphoma / Katharina Aichelin ; Betreuer: Peter Angel." Heidelberg : Universitätsbibliothek Heidelberg, 2020. http://d-nb.info/1211090434/34.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "CAR-T therapy"

1

Furniss, Tilman. The multi-professional handbook of child sexual abuse: Integrated management, therapy, and legal intervention. Routledge, 1991.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Tejirian, Edward J. Sexuality andthe devil: Symbols of love, power, and fear in male psychology. Routledge, 1990.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

InfoNet, BMT. Apr 2020 CAR T-Cell Therapy. Before, During and After. BMT InfoNet, 2020.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

InfoNet, BMT. Jan 2021 CAR T-Cell Therapy. Before, During and After. BMT InfoNet, 2021.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

InfoNet, BMT. Aug 2022 CAR T-Cell Therapy: Before, During and after - English. BMT InfoNet, 2022.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Buka, Richard J., and Ankit J. Kansagra. Fast Facts : CAR T-Cell Therapy: Insight into Current and Future Applications. Karger AG, S., 2021.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

NCCN Guidelines for Patients® Immunotherapy Side Effects CAR T-Cell Therapy. National Comprehensive Cancer Network® (NCCN®), 2024.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Fast Facts : CAR T-Cell Therapy: Insight into Current and Future Applications. Karger AG, S., 2021.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

National Comprehensive Cancer Network® (NCCN®). NCCN Guidelines for Patients® Immunotherapy Side Effects: CAR T-Cell Therapy. National Comprehensive Cancer Network® (NCCN®), 2022.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Young, Ken, Zheming Lu, and Wenbin Qian, eds. The Novel Engineering Strategies and Clinical Progress of Solid Tumor in CAR-T Cell Therapy. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88976-791-5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "CAR-T therapy"

1

Irizarry Gatell, Vivian M., Jeffrey Huang, and Omar A. Castaneda Puglianini. "CAR T-Cell Therapy." In Anesthesia for Oncological Surgery. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-50977-3_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Friedman, Mark T., Kamille A. West, Peyman Bizargity, Kyle Annen, H. Deniz Gur, and Timothy Hilbert. "“CAR T”-esian Thinking." In Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-14638-1_95.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Samal, Priyanka, and Sasmita Das. "Patients on CAR T Cell Therapy." In Critical Care Hematology. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-5565-3_26.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Santani, Bela G., Alok K. Mishra, and Ritesh Thakare. "CAR T-Cell Therapy-Associated Toxicities." In Cell-based Immunotherapies for Cancer. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-88695-9_8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Gutierrez, Cristina, Oren Pasvolsky, and Partow Kebriaei. "CAR T-Cell Therapy and Critical Care Considerations." In Pulmonary and Critical Care Considerations of Hematopoietic Stem Cell Transplantation. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-28797-8_32.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Rasche, Leo, Luca Vago, and Tuna Mutis. "Tumour Escape from CAR-T Cells." In The EBMT/EHA CAR-T Cell Handbook. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_4.

Повний текст джерела
Анотація:
AbstractOver the past decade, CAR-T cells have emerged as one of the most powerful cellular immune therapy approaches in the battle against haematological malignancies. Nonetheless, similar to other immunotherapeutic approaches, tumour cells develop strategies to evade CAR-T cell therapy, often with the support of a highly immunosuppressive and protective tumour microenvironment. To date, antigen loss, immune dysfunction, exhaustion and (microenvironment-mediated) upregulation of antiapoptotic pathways have been identified as major modes of tumour escape from CAR-T cell therapy. This chapter w
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Hu, Jinqiao. "CAR-NK Cell Therapy: A Promising Alternative to CAR-T Cell Therapy." In Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022). Atlantis Press SARL, 2022. http://dx.doi.org/10.2991/978-2-494069-31-2_48.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Zhao, Jingyu. "Research Progress of CAR-T Therapy in Tumor Therapy." In Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022). Atlantis Press SARL, 2022. http://dx.doi.org/10.2991/978-2-494069-31-2_7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Delgado, Julio, Claire Roddie, and Michael Schmitt. "Point-of-Care Production of CAR-T Cells." In The EBMT/EHA CAR-T Cell Handbook. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_8.

Повний текст джерела
Анотація:
AbstractCAR-T cells for clinical application are classified as advanced therapy medicinal products (ATMPs), and their manufacture is subject to laws and regulations governed by the European Medicines Agency (EMA) and by federal and regional authorities. CAR-T cells must be manufactured to achieve good manufacturing practice (GMP) compliance and are defined as potent products manufactured safely according to standardized methods under closely controlled, reproducible, and auditable conditions. BioPharma supplies the vast majority of CAR-T products for patients, but some academic centres have de
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Adada, Mohamad M., Elizabeth L. Siegler, and Saad S. Kenderian. "Combination Therapeutics with CAR-T Cell Therapy." In Cancer Drug Discovery and Development. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-87849-8_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "CAR-T therapy"

1

Gupta, Aarya Kapil, and Gaurav Sharma. "Graph Neural Network and Molecular Docking Simulations of Aptamer-Mediated CAR T-Cell Therapy." In 2024 IEEE MIT Undergraduate Research Technology Conference (URTC). IEEE, 2024. https://doi.org/10.1109/urtc65039.2024.10937542.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Caoimh, Russell, Stanila Raluca, Bacon Larry, Doherty Colin, and Langan Yvonne. "EEG in CAR-T Therapy." In Association of British Neurologists: Annual Meeting Abstracts 2023. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jnnp-2023-abn.48.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Padmanabhan Menon, D., Y. T. Debella, J. A. Marin-Acevedo, S. Fernandez-Bussy, and I. C. Mira-Avendano. "CAR-T Therapy Complicated by Cavitary CMV." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5202.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Gui, Yuyin. "The bottleneck of CAR-T cell therapy." In International Conference on Biological Engineering and Medical Science (ICBIOMed2022), edited by Gary Royle and Steven M. Lipkin. SPIE, 2023. http://dx.doi.org/10.1117/12.2669935.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Zijia, Cheng. "Chimeric-antigen Receptor T (CAR-T) Cell Therapy for Leukemia." In ICBET 2020: 2020 10th International Conference on Biomedical Engineering and Technology. ACM, 2020. http://dx.doi.org/10.1145/3397391.3397451.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Tent, Michiel. "CAR-T cell therapy results in sustained lupus remission." In ACR Convergence 2023. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/00470d55.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Li, Yumeng. "Existing problems and improving methods of CAR-T therapy." In Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), edited by Alan Wang. SPIE, 2024. http://dx.doi.org/10.1117/12.3012990.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Wang, Clara, Haoyang Guo, Hanqin Yang, and Beibo Kang. "Developing CAR-T Therapy for Treating B Cell Malignancies." In International Conference on Biotechnology and Biomedicine. SCITEPRESS - Science and Technology Publications, 2022. http://dx.doi.org/10.5220/0012015100003633.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Roddie, Claire. "23 Origins of CAR-T cell therapy: hematologic perspective." In 13th Annual Meeting of the Lupus Academy, Hybrid Annual Meeting (Amsterdam), September 6–8, 2024. Lupus Foundation of America, 2024. http://dx.doi.org/10.1136/lupus-2024-la.24.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Jing, Ran, Mohamad Najia, Eleanor Meader, et al. "950 Epigenetic reprogramming of iPSC-derived T cells for CAR T cell therapy." In SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.0950.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "CAR-T therapy"

1

Bonnett, Megan. CAR T Cell Therapy. Iowa State University, 2019. http://dx.doi.org/10.31274/cc-20240624-337.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Gilkeson, Kyle. CAR T-Cell Therapy: A New Road to Treat Cancer. Iowa State University, 2020. http://dx.doi.org/10.31274/cc-20240624-339.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Parris, Austin. CAR T-Cell Therapy for Solid Tumors: How Far Are We from Reality? Iowa State University, 2019. http://dx.doi.org/10.31274/cc-20240624-338.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Kumar, Tarun, and Sauvit S. Patil. Reimagining Clioblastoma Multiforme Treatment with the Emerging Role of CAR-T Cell Therapy. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.10.0040.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Zhao, Kangjia, Jiwen Sun, Nanping Shen, et al. Treatment-Related Adverse Events of Chimeric Antigen receptor T-Cell (CAR-T) Cell Therapy in B-cell hematological malignancies in the Pediatric and Young Adult Population: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0034.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Tzfira, Tzvi, Michael Elbaum, and Sharon Wolf. DNA transfer by Agrobacterium: a cooperative interaction of ssDNA, virulence proteins, and plant host factors. United States Department of Agriculture, 2005. http://dx.doi.org/10.32747/2005.7695881.bard.

Повний текст джерела
Анотація:
Agrobacteriumtumefaciensmediates genetic transformation of plants. The possibility of exchanging the natural genes for other DNA has led to Agrobacterium’s emergence as the primary vector for genetic modification of plants. The similarity among eukaryotic mechanisms of nuclear import also suggests use of its active elements as media for non-viral genetic therapy in animals. These considerations motivate the present study of the process that carries DNA of bacterial origin into the host nucleus. The infective pathway of Agrobacterium involves excision of a single-stranded DNA molecule (T-strand
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Magdalinos, Tassos, and Katerina Petrova. Uniform Inference with General Autoregressive Processes. Federal Reserve Bank of New York, 2025. https://doi.org/10.59576/sr.1151.

Повний текст джерела
Анотація:
A unified theory of estimation and inference is developed for an autoregressive process with root in (-∞, ∞) that includes the stationary, local-to-unity, explosive and all intermediate regions. The discontinuity of the limit distribution of the t-statistic outside the stationary region and its dependence on the distribution of the innovations in the explosive regions (-∞, -1) ∪ (1, ∞) are addressed simultaneously. A novel estimation procedure, based on a data-driven combination of a near-stationary and a mildly explosive artificially constructed instrument, delivers mixed-Gaussian limit theor
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "CAR-T therapy" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії